Literature DB >> 33045965

CRISPR/Cas9 Genome Editing Tool: A Promising Tool for Therapeutic Applications on Respiratory Diseases.

Sadiya Bi Shaikh1, Yashodhar Prabhakar Bhandary1.   

Abstract

Respiratory diseases are one of the prime topics of concern in the current era due to improper diagnostics tools. Gene-editing therapy, like Clustered regularly interspaced palindromic repeats- associated nuclease 9 (CRISPR/Cas9), is gaining popularity in pulmonary research, opening up doors to invaluable insights on underlying mechanisms. CRISPR/Cas9 can be considered as a potential gene-editing tool with a scientific community that is helping in the advancement of knowledge in respiratory health and therapy. As an appealing therapeutic tool, we hereby explore the advanced research on the application of CRISPR/Cas9 tools in chronic respiratory diseases such as lung cancer, Acute respiratory distress syndrome (ARDS) and cystic fibrosis (CF). We also address the urgent need to establish this gene-editing tool in various other lung diseases such as asthma, Chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF). The present review introduces CRISPR/Cas9 as a worthy application in targeting epithelial-mesenchymal transition and fibrinolytic system via editing specific genes. Thereby, based on the efficiency of CRISPR/Cas9, it can be considered as a promising therapeutic tool in respiratory health research. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  CRISPR/Cas9; gene editing; gene therapy; lungs-related diseases; pulmonary disease; respiratory diseases

Year:  2020        PMID: 33045965     DOI: 10.2174/1566523220666201012145731

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  2 in total

Review 1.  CRISPR-Cas systems target endogenous genes to impact bacterial physiology and alter mammalian immune responses.

Authors:  Qun Wu; Luqing Cui; Yingying Liu; Rongpeng Li; Menghong Dai; Zhenwei Xia; Min Wu
Journal:  Mol Biomed       Date:  2022-07-20

2.  Anticipating New Treatments for Cystic Fibrosis: A Global Survey of Researchers.

Authors:  Bernardo Cabral; Vito Terlizzi; Onofrio Laselva; Carlos Conte Filho; Fabio Mota
Journal:  J Clin Med       Date:  2022-02-26       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.